A detailed history of Black Rock Inc. transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Black Rock Inc. holds 386,414 shares of BCLI stock, worth $471,425. This represents 0.0% of its overall portfolio holdings.

Number of Shares
386,414
Previous 489,313 21.03%
Holding current value
$471,425
Previous $274,000 52.19%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.34 - $0.74 $34,985 - $76,145
-102,899 Reduced 21.03%
386,414 $131,000
Q1 2024

May 10, 2024

BUY
$0.28 - $0.66 $6,428 - $15,152
22,958 Added 4.92%
489,313 $274,000
Q4 2023

Feb 13, 2024

SELL
$0.15 - $0.4 $158 - $422
-1,056 Reduced 0.23%
466,355 $125,000
Q3 2023

Nov 13, 2023

SELL
$0.2 - $2.08 $3,610 - $37,550
-18,053 Reduced 3.72%
467,411 $93,000
Q2 2023

Aug 11, 2023

BUY
$2.0 - $3.2 $22,744 - $36,390
11,372 Added 2.4%
485,464 $1 Million
Q1 2023

May 12, 2023

BUY
$1.43 - $3.3 $3,317 - $7,656
2,320 Added 0.49%
474,092 $1.56 Million
Q4 2022

Feb 13, 2023

BUY
$1.37 - $4.42 $4,729 - $15,257
3,452 Added 0.74%
471,772 $773,000
Q3 2022

Nov 14, 2022

SELL
$2.55 - $4.42 $13,803 - $23,925
-5,413 Reduced 1.14%
468,320 $2.07 Million
Q2 2022

Aug 12, 2022

SELL
$2.71 - $3.6 $2,105 - $2,797
-777 Reduced 0.16%
473,733 $1.31 Million
Q1 2022

May 12, 2022

BUY
$2.92 - $4.19 $5,939 - $8,522
2,034 Added 0.43%
474,510 $1.59 Million
Q4 2021

Feb 10, 2022

BUY
$2.81 - $4.23 $9,860 - $14,843
3,509 Added 0.75%
472,476 $1.89 Million
Q3 2021

Nov 09, 2021

SELL
$3.14 - $4.09 $16,893 - $22,004
-5,380 Reduced 1.13%
468,967 $1.55 Million
Q2 2021

Aug 11, 2021

BUY
$3.01 - $4.01 $1.43 Million - $1.9 Million
474,347 New
474,347 $1.8 Million

Others Institutions Holding BCLI

About BRAINSTORM CELL THERAPEUTICS INC.


  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $44.5M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.